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Background: Fear of weight gain is a signiﬁcant obstacle to smoking cessation, preventing some smokers
from attempting to quit. Several previous studies of naltrexone yielded promising results for mini-
mization of post-quit weight gain. Given these encouraging ﬁndings, we endeavored to test whether
minimization of weight gain might translate to better quit outcomes for a population that is particularly
concerned about gaining weight upon quitting.
Methods: Smokers (N=172) in this investigation were prospectively randomized to receive either 25mg
naltrexone or placebo for 27 weeks (1 week pre-, 26 weeks post-quit) for minimization of post-quit
weight gain and smoking cessation. All participants received open label therapy with the nicotine patch
for the ﬁrst 8weeks post-quit and behavioral counseling over the 27-week treatment. The 2 pre-speciﬁed
primaryoutcomeswere change inweight for continuously abstinentparticipants andbiologically veriﬁedicotine patch end-of-treatment 7-day point-prevalence abstinence at 26 weeks after the quit date.
Results: The difference in weight at 26 weeks post-quit between the naltrexone and placebo groups
(naltrexone: 6.8 lbs±8.94 vs placebo: 9.7 lbs±9.19, p=0.45) was not statistically different. Seven-day
point-prevalence smoking abstinence rates at 26weeks post-quitwas not signiﬁcantly different between
the 2 groups (naltrexone: 22% vs placebo: 27%, p=0.43).
Conclusions: For smokers high in weight concern, the relatively small reduction in weight gain with
ot wolow-dose naltrexone is n
. Introduction
Fear of weight gain is a signiﬁcant obstacle to smoking cessa-
ion, preventing some smokers fromattempting to quit (Pomerleau
t al., 2001). The effects of pharmacotherapy on minimizing post-
uit weight gain have been mixed (Fiore et al., 2008). For instance,
icotine replacement therapy (NRT) is fairly effective in enhanc-
ng smoking cessation success rates (Silagy et al., 2004). However,
ransdermal nicotine therapy does not reduce hunger or weight
ain signiﬁcantly (Abelin et al., 1989b; Cooper et al., 2005; Rose
t al., 1990). The effects of nicotine gum on delaying weight
ain are stronger than nicotine patch, but the size of this dif-
erence, although signiﬁcant, is modest (Doherty et al., 1996).
 A CONSORT checklist is available as supplementary material with the online
ersion of this article.
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Sustained-release (SR) bupropion hydrochloride has proven effec-
tive in increasing smoking cessation success rates (Ahluwalia et
al., 2002; Hurt et al., 1997; Jorenby et al., 1999; Swan et al., 2003),
and this treatment is moderately successful in helping participants
reduce weight gain upon quitting. Varenicline is also an efﬁca-
cious smoking cessation medication, but it does not signiﬁcantly
reduce post-quit weight gain (Gonzales et al., 2006; Jorenby et al.,
2006). Thus, current pharmacological treatments for smoking ces-
sation aremodestly successful in assisting smokers to quit, but only
nicotine gum and bupropion signiﬁcantly attenuate post-cessation
weight gain. A medication associated with less weight gain upon
quitting could address one of the most important barriers to smok-
ing cessation (Ahluwalia et al., 2002; Hurt et al., 1997).
Clearly, further research is needed to develop medications that
address concern about gaining weight after smoking cessation
(Pomerleau et al., 2001). Not only does concern about weight gain
Open access under CC BY-NC-ND license.prevent smokers from trying to quit, weight-concerned smokers
may also be less successful in achieving abstinence from smoking
because the effort required to control food intake may undermine
efforts to avoid smoking (Hall et al., 1986). In fact, attempts to inte-
grateweight control and smoking cessation efforts have sometimes
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esulted in poorer smoking cessation outcomes (Hall et al., 1992).
hus, a successful intervention that minimizes post-quit weight
ain may be attractive to people who are reluctant to quit or ﬁnd it
ifﬁcult to maintain abstinence due to weight gain.
Naltrexone hydrochloride is a medication that has shown
romise in reducing post-cessation weight gain and may therefore
ddress weight concerns (King et al., 2006; Krishnan-Sarin et al.,
003; O’Malley et al., 2006; Toll et al., 2008). Several reasons have
een suggested for why naltrexone may be effective in minimiz-
ng post-quit weight gain. Animal models have implicated opioid
ntagonists indecreasedbodyweight and food intake (Bodnaret al.,
003), and opioid receptor knockoutmice have shown resistance
o obesity (Tabarin et al., 2005).
Several randomized controlled studies have shown that naltrex-
ne signiﬁcantly reducespost-quitweightgain.A small preliminary
tudy in 32 smokers found that naltrexone in combination with
icotine patch suppressed weight gain compared to placebo alone
Krishnan-Sarin et al., 2003). Subsequently, King et al. (2006)
onducted an 8-week placebo-controlled study of naltrexone
50mg/day) combined with the nicotine patch with 110 subjects
nd found that participants in the naltrexone group gained sig-
iﬁcantly less weight (1.5 pounds) as compared to those in the
lacebo+nicotine patch group (4.2 pounds). The largest clinical
rial conducted to date was a dose ranging study of naltrexone
placebo, 25mg, 50mg, or 100mg – taken daily) in combination
ith transdermal nicotine patch in 400 participants (O’Malley
t al., 2006). The highest dose showed promise for promoting
moking abstinence, but effects on weight were not signiﬁcant.
n contrast, low-dose (25mg/day) naltrexone signiﬁcantly reduced
ost-cessation weight gain over 6 weeks, with participants show-
ng an average weight gain of 1.5 pounds on this dose compared to
.2 pounds for those taking placebo, although it did not increase
moking abstinence. Based on the weight gain ﬁndings, Toll et
l. (2008) treated 20 weight-concerned smokers combining 25mg
altrexone with 300mg bupropion SR, and showed that continu-
usly abstinent participants in the naltrexone+bupropion group
ained less weight (1.67 pounds) than those in a matched group
f patients who received bupropion only (3.17 pounds; p=0.35;
ohen’s d=0.56) (Toll et al., 2008). Consistent with these ﬁndings,
recent review concluded that naltrexone showed promise as a
otential drug treatment for preventing post smoking cessation
eight gain (Parsons et al., 2009).
Although naltrexone appears to reduce weight gain after quit-
ing, effects on smoking cessation have been inconclusive. Several
tudies showed that naltrexone did not help participants quit
moking or were mixed (Ahmadi et al., 2003; King et al., 2006;
oll et al., 2008; Wong et al., 1999), whereas other studies showed
hat naltrexone may be beneﬁcial for smoking cessation (Covey
t al., 1999; Krishnan-Sarin et al., 2003; O’Malley et al., 2006).
nly the small pilot study by Toll et al. (2008) selected weight-
oncerned smokers. Prior studies tested short-term treatment from
to 8 weeks; whereas most smokers continue to gain weight over
he ﬁrst 6-months following smoking cessation (Hall et al., 1986;
lesges et al., 1997; Pirie et al., 1992).
In the present study, we tested the hypothesis that minimiza-
ion of weight gain with low-dose naltrexone might translate to
etter quit outcomes for a population of weight-concerned smok-
rs who believe that smoking helps control their weight. The study
esign was a double-blind placebo-controlled trial of 25mg of nal-
rexone or placebo administered for 1 week pre-quit and for 26
eeks post-quit, the major period of risk for weight gain followingmoking cessation. In addition, all subjects received transdermal
icotine replacement for 8weeks following their quit date andbrief
moking cessation counseling throughout the entire treatment
eriod.Wehypothesized thatparticipantswhoreceivednaltrexone
ould report higher rates of abstinence fromcigarette smoking andendence 111 (2010) 200–206 201
lowerpost-quitweight gain compared toparticipantswho received
placebo.
2. Methods
2.1. Participants
Onehundredseventy-twocigarette smokerswereenrolled.Recruitmentwasvia
advertisements placed in local media outlets, mailings (to past participants, poten-
tial participants, and health care professionals), ﬂiers, fax referrals from healthcare
providers, press releases, and websites.
To be eligible, all smokers needed to be classiﬁed as weight-concerned smokers
based on 2 criteria. Concern about gaining weight after quitting was assessed using
the questions Perkins et al. (2001) used to deﬁneweight concern in their clinical trial
ofCBT. These included“Howconcernedareyouaboutgainingweightafterquitting?”
and “How concerned would you be if quitting smoking caused you to permanently
gain 10 lbs?” Consistentwith their criteria, a rating of 50 or higher on a 100mmscale
on either question qualiﬁed the subject on this criterion. Smoking tomanageweight
was assessed with the weight control subscale of the Smoking Consequences Ques-
tionnaire [SCQ] (Copeland et al., 1995) on which participants rate their expectations
about the consequences of smoking a cigarette on a scale of 0-9 with 1 being “com-
pletely unlikely” and 9 being “completely likely”. Five items make up this subscale
(alpha=0.96) and include “smoking keeps my weight down”, “cigarettes keep me
from eating more than I should”, “smoking helps me control my weight’, “cigarettes
keep me from overeating”, and “smoking controls my appetite”. A mean rating of 6
or above (“somewhat likely”) qualiﬁed participants on this criterion.
Other inclusion and exclusion criteria were age 18 and older, willingness and
ability to givewritten consent, smoking greater than10 cigarettes per day for at least
1 year, at least 1 prior attempt to stop smoking, baseline expired carbon monoxide
(CO) level of at least 10ppm, weight of at least 100 lbs, English speaking, and only 1
participant per household. Exclusion criteria included pregnant or nursing women
or women attempting to conceive, unstable cardiac disease, history of dermatoses,
current alcohol or drug dependence other than nicotine dependence, serious cur-
rent neurologic, psychiatric, suicidal risk or medical illness, chronic pain conditions
necessitating opioid treatment, history of cirrhosis or of signiﬁcant hepatocellu-
lar injury, current use of smokeless tobacco, pipes, cigars, nicotine gum, patch,
lozenge, inhaler, or nasal spray, patients requiring concomitant therapy with any
psychotropic drug or on any drug with a psychotropic component [except those
who were on a stable dose of an Selective Serotonin Reuptake Inhibitor for at least 2
months for the indications ofMajorDepressiveDisorder, Premenstrual Syndromeor
PremenstrualDysphoricDisorder], subjectswith a positive opioid urine drug screen,
current use of opioids, or currently on a medically prescribed diet. The institutional
review board of the Yale University School of Medicine approved this study.
2.2. Procedures
Following written informed consent, patients completed baseline assessments,
a physical examination, and laboratory testing. Eligible participants were random-
ized to conditions, with blocked stratiﬁed (for gender) randomization due to the
fact that weight-concerned samples are usually mostly female (Perkins et al., 2001).
Random sequence was provided by one of the authors (RW) to the pharmacist who
assignedparticipants; all otherswereblind to treatmentassignment.All participants
were seen at a community mental health center. Participants were randomized
between February 3, 2005 and September 25, 2008, and the last treatment appoint-
ment was completed on April 27, 2009.
2.3. Medication conditions
Participants received placebo or 25-mg naltrexone daily beginning the week
before quitting. Naltrexone (Depade,Mallinckrodt Pharmaceuticals)was titrated for
the ﬁrst 2 days (i.e., 12.5-mg for 1 day, then 25-mg thereafter) then taken for a total
of 27weeks (1week pre- and 26weeks post-quit). Naltrexonemedication in opaque
capsules was dispensed in bottles, with the ﬁrst dose in an individual glassine enve-
lope within the bottle. Participants received 21mg transdermal nicotine patches
(NicodermCQ,GlaxoSmithKline) for 6weeks, then14mgpatches for 2weeks, begin-
ning on their quit date. Participants were instructed to take their naltrexone and
replace their patch at the same time. Based on tolerability, dose reductions or dis-
continuation were permitted with the option to continue the nicotine patch and
counseling.
2.4. Counseling
The counselingwas adapted from the cognitive-behavioral therapy (CBT) proto-
col forweight-concerned smokers created by Perkins et al. (2001) and the treatment
manual was developed in collaboration with Dr. Michele Levine, who assisted in
implementation and development of the source CBT protocol. The ﬁrst session with
the nurse lasted 45min and subsequent weekly sessions with a research assistant
supervised by an investigator (BAT) lasted 5–15min, with longer sessions occurring
in earlier meetings. Counseling occurred weekly for the ﬁrst 4 weeks, bi-weekly
twice, then monthly. Handouts described the beneﬁts of quitting smoking and
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Table 1
Baseline characteristics.
Naltrexone (N=87) Placebo (N=85) Overall (N=172) p-Values
Age (year) 43.2±10.0 45.5±11.25 44.4±10.67 0.152
Male (%) 28.7 28.2 28.5 0.942
White (%) 85.1 83.5 84.3 0.783
Body mass index 28.5±6.36 28.3±6.01 28.4±6.16 0.872
Education (%) 0.587
High-school graduate or less 32.2 34.9 33.5
Some education after high school 43.7 36.1 40
College graduate or more 24.1 28.9 26.5
Marital status (%) 0.86
Married or cohabitating 43.7 41.7 42.7
Divorced or separated 26.4 32.1 29.2
Never married 27.6 23.8 25.7
Widowed 2.3 2.4 2.3
Full-time employment (%) 75.3 61.5 68.5 0.054
No. of cigarettes smoked per day 22.1±10.27 22.2±8.62 22.2±9.46 0.946
Years of smoking cigarettes 26.4±10.20 27.6±11.47 27.0±10.82 0.466
Expired carbon monoxide (ppm) 25.6±11.14 25.3±10.42 25.5±10.76 0.839
Serum cotinine (ng/ml)
Fagerstrom score 5.5±1.96 5.9±2.11 5.7±2.04 0.185
Other smokers in household (%) 29.1 36.9 32.9 0.277
CES-D score 8.4±5.89 8.2±6.68 8.3±6.27 0.846
Perkins 1 89.9±12.75 89.3±11.88 89.6±12.29 0.742
Perkins 2 74.3±26.75 78.0±24.33 76.1±25.58 0.324
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nSCQ weight control subscale 33.6±7.83
Drinker (%) 75.9
Percentage of days abstinent (drinker) 71.9±30.98
Drinks per drinking day (drinker) 2.5±1.51
ddressedaspectsofquitting for thispopulation (e.g., relative riskofweightgain, tips
o eat a balanced diet, drink water, and exercise). However, following the model of
erkins et al. (2001) participantswere asked to not diet and accept amodest amount
fweight gainwhile theywere engaged in active treatment. The recommendation to
esist dieting during treatment was based on research suggesting that interventions
hat advocate dieting for weight loss may be counterproductive to smoking cessa-
ion. One hypothesis is that those who restrain themselves from eating in order to
void weight gain make themselves vulnerable to relapse by making smoking more
einforcing. The preclinical literature provides substantial evidence demonstrating
hat food deprivation enhances an animal’s responding for drugs of abuse (Alsene
t al., 2003; Carroll et al., 1979; Carroll and Meisch, 1981; De La Garza and Johanson,
987), including nicotine (Lang et al., 1977). Withdrawal may be more pronounced
ith food restriction, an idea supported by data demonstrating that carbohydrate
onsumption or glucose tablets reduced nicotine withdrawal or the urge to smoke
Bowen et al., 1991; West et al., 1990; West and Willis, 1998) and that dextrose
ablets compared to placebo improved smoking abstinence rates over 4 weeks in 1
tudy (West et al., 1999).
.5. Assessments
Participants completed a core battery with questions about demographics,
moking variables, mood, alcohol use, and other areas of functioning. Diagnos-
ic information was obtained with the Fagerström Test for Nicotine Dependence
Heatherton et al., 1991), an alcohol screening questionnaire (AUDIT) (Babor et
l., 1992), and the Structured Clinical Interview for DSM-IV Axis I Disorders eat-
ng disorder, alcohol, and depression modules (First et al., 1996). At each weekly
ppointment, weight, CO levels and reports of daily tobacco and alcohol consump-
ion were obtained, the latter using the Timeline Follow-back Interview (TLFB)
eginning 30 days prior to screening (Brown et al., 1988; Sobell and Sobell, 2003).
articipant weight (in street clothes, without shoes) was measured using a cali-
rated balance beam scale. If a participant dropped out of treatment, we attempted
o obtain their smoking data by phone. If they reported abstinence, they were only
oded as abstinent when an in-person breath CO measurement was obtain bio-
ogically verifying their self-report. Serum cotinine was measured at intake and
ost-treatment follow-ups. Other weekly self-reports included the Questionnaire
n Smoking Urges-Brief (QSU-Brief) (Cox et al., 2001) and the Minnesota Nicotine
ithdrawal Scale (MNWS) (Hughes, 1992; Toll et al., 2007).
A checklist of common adverse events for naltrexone and for nicotine patch was
dministered weekly with other concerns elicited with questioning. Liver function
ests (LFTs) were obtained at intake, 4, 14, and 26 weeks post-randomization..6. Data analysis
All patients who were randomized comprised the primary ITT population. The
pre-speciﬁed primary outcomes were change in weight for continuously absti-
ent participants andbiologically veriﬁed end-of-treatment 7-daypoint-prevalence34.2±8.04 33.9±7.92 0.64
78.8 77.3 0.643
72.9±31.33 72.4±31.04 0.859
2.5±1.27 2.5±1.39 0.843
abstinence at 26 weeks after the quit date. Change in weight from baseline was
analyzed with 1-way ANOVA GLM for abstainers who completed treatment. A sen-
sitivity analysis was performed using a linear mixed effects model with weight as
the response, and time, treatment and time× treatment entered asﬁxed effectswith
baselineweight entered as a covariate. The primary smoking cessation outcomewas
point-prevalence abstinence over the past 7 days at 26 weeks after the quit date
and the secondary smoking cessation outcome was point-prevalence abstinence
over the past 7 days at 6 weeks after the quit date to allow comparisons to our ear-
lier 6-week study (O’Malley et al., 2006). Self-reported abstinence (not even a puff)
was veriﬁed by exhaled CO level ≤10ppm. Participants who dropped out or missed
multiple appointments were considered failures. A single missed appointment was
coded abstinent only if abstinence was veriﬁed at the appointments before and
after the missed session. For baseline group comparisons, chi-square tests and GLM
were used for categorical and continuous variables, respectively. Smoking absti-
nence outcomes (yes/no) were initially analyzed using a logistic regression model
including treatment condition (naltrexone vs placebo), gender (male vs female), and
condition×gender. After this, if we found that the interaction was not signiﬁcant,
we tested a reduced, main effects only model including only treatment condition
(naltrexone vs placebo) and gender (male vs female).
Secondary analyses of cigarettes smoked per day, craving (QSU-Brief scores),
and withdrawal (MNWS scores) were analyzed using linear mixed effects models
from1week to 26weeks post-quit including gender as a covariate. Baseline (intake)
was also treated as a covariate in the smoked per day analysis.
3. Results
3.1. Patient characteristics and disposition
Of the 301 participants who were screened, 172 were random-
ized to the naltrexone or placebo condition. For the intent-to-treat
population, Table 1 shows the between-group distribution of
baseline demographic and other patient characteristics. The two
treatment groups are well-balanced on all factors, and no variables
differ by group at p<0.05.
Of the 172 subjects randomized, there were 87 subjects in the
active treatment arm and 85 subjects in the control group. Fig. 1
presents patient disposition data. Of the 87 active group partici-
pants, 28 completed treatment. Similarly, for the control group, of
the 85 participants, 30 completed treatment. Of note, this study
was initially powered based on a total sample size of 270 smokers.
However, based on an interim analysis, it was decided to end the
study after recruitment of 172 participants.
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Fig. 1. Study ﬂ
Table 2a
Weight gain over 26- and 6-weeks post-quita.
Outcome Placebo M (SD) 25mg M (SD) F p
Weight gain over 26 weeks 9.71 ± 9.19 6.75 ± 8.94 0.58 0.45
w
3
w
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T
OWeight gain over 6 weeks 2.19 ± 4.20 2.53 ± 4.58 0.07 0.79
a All groups also received 21mg transdermal nicotine replacement for the ﬁrst 8
eeks post-quit.
.2. Weight gain
We studied the change in weight over time, beginning at 1
eek post-quit until the study end at week 26, among those who
chieved total smoking abstinence. As presented in Table 2a, on
verage, there was a weight increase of 6.8 pounds (SD=8.94) in
he active group compared to an increase of 9.7 pounds (SD=9.19)
n the control group. Thus, both treatment groups had a weight
ncrease that was not statistically different (p=0.45). When this
roup of subjects was evaluated at the intermediate time point of
weeks, there was a weight increase from week 1 to week 6 of 2.5
ounds (SD=4.58) in the active treatment group and 2.2 pounds
SD=4.20) in the control group (see Table 2a). Again, this difference
as not statistically signiﬁcant (p=0.79).
.3. Smoking abstinenceAs displayed in Table 2b, for the primary study endpoint of
oint-prevalence abstinence at week 26, the ITT population had
9 of 87 (22%) active treatment subjects belonging to this category
ompared to 23 of 85 (27%) of the placebo subjects (p=0.43). Of 87
able 2b
dds of 26- and 6-week point-prevalence abstinencea.
Outcome Placebo % (n)
26-Week point-prevalence abstinence 27.06 (23)
6-Week point-prevalence abstinence 50.59 (43)
a All groups also received 21mg transdermal nicotine replacement for the ﬁrst 8 week
b Odds ratios comparing 25mg dose to placebo are reported along with 2-sided 95% coowchart.
active treatment ITT subjects, 33 of 87 (38%) subjects in the nal-
trexone condition achieved point-prevalence abstinence at week 6
compared to43of 85 (51%) ITT subjects in theplaceboarm (p=0.10;
see Table 2b).
3.4. Cigarettes smoked per week and symptoms of withdrawal
and craving
A secondary endpoint that was evaluated was amount smoked
per occasion from 1 week to 26 weeks post-quit. As shown in
Fig. 2, there was a non-signiﬁcant interaction of condition-by-
week [p=0.05], such that the naltrexone group (n=67; M=7.10,
SD=8.43) smoked slightly fewer cigarettes per occasion over time
than those in the placebo group (n=67; M=7.85, SD=8.35) at 26
weeks post-quit. Neither craving nor withdrawal scores were sig-
niﬁcantly different for scores averaged over time.
3.5. Safety
Four serious adverse events (SAEs; 3 requiring an overnight
hospitalization and 1 cancer diagnosis) occurred during the study.
Two of these SAEs (anxiety, abnormal EKG) were in the naltrexone
condition, and two (cut ﬁngers with saw, diagnosis of thyroid can-
cer) were in the placebo condition. All of these SAEs were deemed
unlikely to be related to study participation. Two participants were
withdrawn by the PI including a subject who reported a blood clot
before starting the studymedication and a participantwho initially
denied opioid use at screening but later had a positive opioid drug
test. Consistent with the principle of ITT, these two participants
25mg % (n) Odds ratio (95% CI)b p
21.84 (19) 0.75 (0.37–1.51) 0.43
37.93 (33) 0.60 (0.33–1.09) 0.10
s post-quit.
nﬁdence intervals (95% CI).
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ere included in study analyses. Excluding them did not alter the
rimary study outcome analyses of weight and smoking.
LFT values were evaluated using cutoff values of 3 times the
pper limit for ALT and AST and over 10% of the upper limit for total
ilirubin during treatment. No subjects were found to be above
hese cutoff values at any time during the study. The percentage
f unique participants reporting non-serious adverse events rated
oderate or severe with a prevalence of ≥5% differed by treatment
roup for depression and decreased appetite [in each case there
ere4 (5%)naltrexone subjects vs0 (0%)placebo subjects,X2 = 4.21,
= 0.04].
. Discussion
This was a placebo-controlled double-blind investigation of
ow-dose naltrexone for smoking cessation with minimized post-
uit weight gain. Although there was a small numerical difference
n weight at 6 months after quitting smoking that favored the
altrexone group, this difference was not statistically signiﬁcant.
urthermore, rates of smoking cessation, although also statistically
on-signiﬁcant, numerically favored the placebo group. Thus, we
onclude that the relatively small beneﬁts on weight do not off-
et the potentially higher rates of relapse to smoking for highly
eight-concerned smokers.
The average weight gain at 6 weeks post-quit in the placebo
roup was 2.5 pounds. This value is lower than the mean weight
ain of 4.2 pounds at 6 weeks post-quit in the placebo group in our
ose ranging study of naltrexone (O’Malley et al., 2006), and 4.2
ounds at 4 weeks post-quit in King et al.’s study of 50mg naltrex-
ne (King et al., 2006). It is also lower than the 3.17 pound weight
ain 6 weeks after quitting that we found in smokers taking bupro-
ion SRonly in our pilot study of naltrexoneplus bupropion SR (Toll
t al., 2008). Indeed, other investigations noting that bupropion SR
igniﬁcantly reduces weight gain over 6–8 weeks post-quit have
ound weight gain in the range of 3.3–3.7 pounds (Hurt et al., 1997;
orenby et al., 1999) that is still higher than the mere 2.5 pounds
ound in the present sample for the placebo group. Weight gain at
6 weeks post-quit is generally not reported. However, among the
ew studies that have reported this variable, the weight gain of 9.7
ounds in the placebo group in the present study is comparable to
r less than weight gain reported in other investigations that have
sed bupropion SR [9.9–10.6 pounds (Hurt et al., 1997; Tønnesen et
l., 2003)] or no medications [12.0 pounds (Klesges et al., 1997)] for
moking cessation. Thus, in the short-term, thepopulationof smok-
rs evaluated in this study appears to gain considerably less weight
ost-quit compared to smokers in prior studies taking placebo nal-
rexone or bupropion SR, a drug known to suppress weight gain. Inendence 111 (2010) 200–206
the long-term, this population of smokers still appears to gain less
than or equal to the weight gain found in other treatment studies.
The most likely reason for the overall low weight gain in this
sample relates to the study population (i.e., weight-concerned
smokers). Indeed, at 4 weeks post-quit, Perkins et al. found an
average weight gain of 2.2 pounds in their control group of weight-
concerned smokers. Another related plausible explanation is the
counseling protocol implemented in conjunction with the medi-
cations regimen. This protocol was adapted from the CBT manual
employed by Perkins et al. (2001). Importantly, Perkins et al. (2001)
found evidence that a CBT intervention to reduce weight concerns
that speciﬁcally discouraged dieting resulted in superior quit rates
compared to both weight control and standard counseling inter-
ventions. Our adaptation was designed to be less time-intensive
(i.e., 5–15min individual sessions vs 90-min group sessions). Even
so, the same overall theoretical rationale was employed, in which
dieting was explicitly discouraged, and this may have led to less
weight gain for both study groups. Although this is a hypothesis
thatwouldneed to be validated in another study, if found to be true,
the much briefer smoking protocol used in the present study could
be used by primary care providers to address smoking cessation in
weight-concerned smokers.
Even though naltrexone does not appear to reduce weight gain
in the speciﬁc subpopulation of smokers tested in the current study
(i.e., highly weight-concerned smokers who report that smoking
helps manage their weight), most studies ﬁnd that naltrexone
reduces post-cessation weight gain (King et al., 2006; Krishnan-
Sarin et al., 2003; O’Malley et al., 2006; Toll et al., 2008). There are
other sub-populations of smokers for whom minimization of post-
quit weight gain may be valued. For instance, overweight smokers
who binge eat have important reasons to appreciate less weight
gain upon quitting smoking (White et al., 2010). Similarly, the com-
bination of naltrexone and other pharmacological treatments may
be effective for some smokers [e.g., overweight and obese (Wilcox
et al., 2010)]. In addition, greater smoking cessationweight gainhas
been associated with disinhibited eating and eating in response to
negative affect (Hudmon et al., 1999). Whereas the current study
tested individuals with the cognitive features of eating disturbance
(i.e., elevatedweight concerns), future studies should consider test-
ing naltrexone in populationswith the behavioral features of eating
disturbance (such as emotional eating, excessive overeating, and
binge eating).
The evidence regarding smoking cessation outcomes with nal-
trexone has been inconsistent with multiple negative (Ahmadi et
al., 2003; King et al., 2006; Toll et al., 2008; Wong et al., 1999),
mixed (King et al., 2006) and positive (Covey et al., 1999; Krishnan-
Sarin et al., 2003; O’Malley et al., 2006) studies. The present study
which used 25mg daily adds to accumulating evidence that nal-
trexoneeitherdoesnotaid in smokingcessationorhasaweakeffect
(Davidet al., 2001). Themostpromising results inprior studieswere
found for higher dose naltrexone (100mg daily), and future studies
should be conducted to replicate this ﬁnding (O’Malley et al., 2006).
Research might also evaluate whether naltrexone augmentation of
ﬁrst-line smoking cessation therapies will improve smoking ces-
sation outcomes for heavy drinking smokers (Leeman et al., 2008)
given the documented efﬁcacy of naltrexone for reducing heavy
drinking (O’Malley et al., 2009; Pettinati et al., 2006).
The only adverse events to show medication effects were
decreasedappetite anddepression,withhigher rates in thenaltrex-
one group. Although these differenceswere statistically signiﬁcant,
the numerical frequency was relatively low. Moreover, decreased
appetite was expected in the naltrexone group.
There are several limitations to this investigation. Our sample
was comprised primarily of Caucasian smokers, and recruitment
via media outlets (e.g., the internet, television, and newspapers)
potentially yielded a highly motivated group of smokers. More-
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ver, the population enrolled is one with high weight concern who
eported smoking to manage their weight. We also tested only 1
ose of naltrexone (i.e., 25mg naltrexone vs placebo), and testing
igher doses might have yielded different results. The long study
reatment length (i.e., 26 weeks) may have contributed to high
ates of drop out. Although participantswere instructed not to diet,
dherence to these instructionswasnotmeasured, andparticipants
ight have engaged in weight control practices that could possibly
lter study outcomes.
In summary, treatment with low-dose naltrexone does not
igniﬁcantly reduce weight gain or improve smoking cessation
n highly weight-concerned smokers. Given that this population
ained relatively little weight even on placebo, cognitive inter-
entions to reduce weight concerns (Perkins et al., 2001) in
ombination with approved smoking cessation pharmacotherapy
repreferable. Nevertheless, theremaybeother sub-populations of
mokers at risk of substantialweight gain following smoking cessa-
ion for whom the weight suppressing effects of naltrexone might
e of beneﬁt.
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